Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions

Bibliography

• LOWY FD: Staphylococcus aureus infections. New Engl. J. Med. (1998) 339(8):520-532.
   PubMed Web of Science ®Google Scholar
• TALBOT GH, BRADLEY J, EDWARDS JE, GILBERT D, SCHELD M, BARTLETT JG: Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. (2006) 42(5):657-668.
   PubMed Web of Science ®Google Scholar
• RYBAK MJ: Therapeutic options for Gram-positive infections. J. Hosp. Infect. (2001) 49(Suppl. A):S25-S32.
   PubMed Web of Science ®Google Scholar
• GOSBELL IB: Epidemiology, clinical features and management of infections due to community methicillin-resistant Staphylococcus aureus (cMRSA). Intern. Med. J. (2005) 35:S120-S135.
   PubMed Web of Science ®Google Scholar
• CHAMBERS HF: The changing epidemiology of Staphylococcus aureus. Emerg. Infect. Dis. (2001) 7(2):178-182.
   PubMed Web of Science ®Google Scholar
• KUEHNERT MJ, KRUSZON-MORAN D, HILL HA et al.: Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001 – 2002. J. Infect. Dis. (2006) 193(2):172-179.
   PubMed Web of Science ®Google Scholar
• COLLIGNON P, NIMMO GR, GOTTLIEB T, GOSBELL IB; on behalf of the AUSTRALIAN GROUP ON ANTIMICROBIAL RESISTANCE: Staphylococcus aureus bacteremia Australia. Emerg. Infect. Dis. (2005) 11(4):554-561.
   PubMed Web of Science ®Google Scholar
• VON EIFF C, BECKER K, MACHKA K, STAMMER H, PETERS G: Nasal carriage as a source of Staphylococcus aureus bacteremia. New Engl. J. Med. (2001) 344(1):11-16.
   PubMed Web of Science ®Google Scholar
• KLUYTMANS JA, MOUTON JW, IJZERMAN EP et al.: Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J. Infect. Dis. (1995) 171(1):216-219.
   PubMed Web of Science ®Google Scholar
• JEVONS MP: “Celbenin”-resistant staphylococci. Br. Med. J. (1961) 124:124-125.
   Google Scholar
• HARTMAN BJ, TOMASZ A: Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J. Bacteriol. (1984) 158(2):513-516.
   PubMed Web of Science ®Google Scholar
• MATSUHASHI M, SONG MD, ISHIMOTO F et al.: Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to β-lactam antibiotics in Staphylococcus aureus. J. Bacteriol. (1986) 167(3):975-980.
   PubMed Web of Science ®Google Scholar
• DERESINSKI S: Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic and therapeutic odyssey. Clin. Infect. Dis. (2005) 40(4):562-573.
   PubMed Web of Science ®Google Scholar
• NATIONAL NOSOCOMIALINFECTIONS SURVEILLANCE SYSTEM: National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control. (2003) 31(8):481-498.
   PubMed Web of Science ®Google Scholar
• FLUIT AC, WIELDERS CLC, VERHOEF J, SCHMITZ FJ: Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 University Hospitals Participating in the European SENTRY Study. J. Clin. Microbiol. (2001) 39(10):3727-3732.
   PubMed Web of Science ®Google Scholar
• COSGROVE SE, SAKOULAS G, PERENCEVICH, SCHWABER MJ, KARCHMER AW, CARMELI Y: Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. (2003) 36(1):53-59.
   PubMed Web of Science ®Google Scholar
• RUBIN RJ, HARRINGTON CA. POON A, DIETRICH K, GREENE JA, MOIDUDDIN A: The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg. Infect. Dis. (1999) 5(1):9-17.
   PubMed Web of Science ®Google Scholar
• VERHOEF J: Stopping short the spread of methicillin-resistant Staphylococcus aureus. Can. Med. Assoc. J. (2001) 165(1):31-32.
   Web of Science ®Google Scholar
• STENHEM M, ORTQVIST A, RINGBERG H et al.: Epidemiology of methicillin-resistant Staphylococcus aureus in Sweden 2000 – 2003, increasing incidence and regional differences. BMC Infect. Dis. (2006) 6:30.
   PubMed Web of Science ®Google Scholar
• NOSKIN GA, RUBIN RJ, SCHENTAG JJ et al.: The burden of Staphylococcus aureus infections on hospitals in the United States. Arch. Intern. Med. (2005) 165(15):1756-1761.
   PubMed Web of Science ®Google Scholar
• GOULD IM: Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control. Int. J. Antimicrob. Agents (2006) 28:379-384.
   PubMed Web of Science ®Google Scholar
• ENGEMANN JJ, CARMELI Y, COSGROVE SA et al.: Adverse clinical and economic outcomes attributable to methicillin resistance among subjects with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. (2003) 36(5):592-598.
   PubMed Web of Science ®Google Scholar
• LODISE TP, MCKINNON PS: Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diag. Microbiol. Infect. Dis. (2005) 52(2):113-122.
   PubMed Web of Science ®Google Scholar
• CHAIX C, DURAND-ZALESKI I, ALBERTI C, BRUN-BUISSON C: Control of endemic methicillin-resistant Staphylococcus aureus. A cost–benefit analysis in an intensive care unit. J. Am. Med. Assoc. (1999) 282(18):1745-1751.
   PubMed Web of Science ®Google Scholar
• JOHNSON PD, HOWDEN BP, BENNETT CM. Staphylococcus aureus: a guide for the perplexed. The differences between community-acquired and health care-associated MRSA explained. Med. J. Aust. (2006) 184(8):374-375.
   PubMed Web of Science ®Google Scholar
• KING MD, HUMPHREY BJ, WANG YF, KOURBATOVA EV, RAY SM, BLUMBERG HM: Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. (2006) 144(3):309-317.
   PubMed Web of Science ®Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): Methicillin-resistant Staphylococcus aureus infections in correctional facilities – Georgia, California and Texas, 2001 – 2003. MMWR (2003) 52:992-996.
   PubMedGoogle Scholar
• BEGIER EM, FRENETTE K, BARRETT NL et al.: A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin. Infect. Dis. (2004) 39(10):1446-1453.
   PubMed Web of Science ®Google Scholar
• ZINDERMAN CE: Community-acquired methicillin-resistant Staphylococcus aureus among military recruits. Emerg. Infect. Dis. (2004) 10(5):941-944.
   PubMed Web of Science ®Google Scholar
• GROOM AV, WOLSEY DH, NAIMI TS et al.: Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. J. Am. Med. Assoc. (2001) 286(10):1201-1205.
   PubMed Web of Science ®Google Scholar
• NAIMI TS, LEDELL KH, COMO-SABETTI K et al.: Comparison of community and health care-associated methicillin-resistant Staphylococcus aureus infection. J. Am. Med. Assoc. (2003) 290(22):2976-2984.
   PubMed Web of Science ®Google Scholar
• SARAVOLATZ LD, MARKOWITZ N, ARKING L, POHLOD D, FISHER E: Methicillin-resistant Staphylococcus aureus. Epidemiologic observation during a community-acquired outbreak. Ann. Intern. Med. (1982) 96(1):11-16.
   PubMed Web of Science ®Google Scholar
• NIMMO GR, COOMBS GW, PEARSON JC et al.; on behalf of the AUSTRALIAN GROUP ON ANTIMICROBIAL RESISTANCE (AGAR): Methicillin-resistant Staphylococcus aureus in the Australian community: an evolving epidemic. Med. J. Aust. (2006) 184(8):384-388.
   PubMed Web of Science ®Google Scholar
• GILLET Y, ISSARTEL B, VANHEMS P: Association between Staphylococcus aureus strains carrying gene for panton-valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet (2002) 359(9308):753-759.
   PubMed Web of Science ®Google Scholar
• VOYICH JM, OTTO M, MATHEMA B et al.: Is panton-valentine leukocidin the major virulence determinant in community-associated methicillin resistant Staphylococcus aureus sisease? J. Infect. Dis. (2006) 194:1761-1770.
   PubMed Web of Science ®Google Scholar
• HOWDEN BP, WARD PB, CHARLES PG et al.: Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. (2004) 38(4):521-528.
   PubMed Web of Science ®Google Scholar
• HOWDEN BP: Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). Int. Med. J. (2005) 35:S136-S140.
   Web of Science ®Google Scholar
• CHARLES PG, WARD PB, JOHNSON PD, HOWDEN BP, GRAYSON ML: Clinical features associated with bacteremia due to heterogeneous vancomycin intermediate Staphylococcus aureus. Clin. Infect. Dis. (2004) 38(3):448-451.
   PubMed Web of Science ®Google Scholar
• TENOVER FC, MCDONALD LC: Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr. Opin. Infect. Dis. (2005) 18(4):300-305.
   PubMed Web of Science ®Google Scholar
• CUI L, IWAMOTO A, LIAN JQ et al.: Novel mechanism of antibiotic resistance originating in vancomycin intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. (2006) 50(2):428-438.
   PubMed Web of Science ®Google Scholar
• CLARK NC, WEIGEL LM, PATEL JB, TENOVER FC: Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicrob. Agents Chemother. (2005) 49(1):470-472.
   PubMed Web of Science ®Google Scholar
• TENOVER FC, WEIGEL LM, APPELBAUM PC et al.: Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. (2004) 48(1):275-280.
   PubMed Web of Science ®Google Scholar
• FATTOM A, SCHNEERSON R, WATSON DC et al.: Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect. Immun. (1993) 61(3):1023-1032.
   PubMed Web of Science ®Google Scholar
• SHINEFIELD H, BALCK S, FATTOM A et al.: Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. New Engl. J. Med. (2002) 346(7):491-496.
   PubMed Web of Science ®Google Scholar
• WEEMS JJ Jr, STEINBERG JP, FILLER S et al.: Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. (2006) 50(8):2751-2755.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-LOPEZ S, KIM HS, CHOI EC et al.: Anti-bacterial agents based on the cyclin D, l-alpha-peptide architecture. Nature (2001) 412(6845):452-455.
   PubMed Web of Science ®Google Scholar
• YAMADA M, NAKAMURA K, SADO-SAGANAKA H et al.: Therapeutic effect of modified oligopeptides from the beetle Allomyrina dichotoma on methicillin-resistant Staphylococcus aureus (MRSA) infection in mice. J. Vet. Med. Sci. (2005) 67(10):1005-1011.
   PubMed Web of Science ®Google Scholar
• TOMASINSIG L, ZANETTI M: The cathelicidins – structure, function and evolution. Curr. Prot. Peptide Sci. (2005) 6:23-34.
   PubMed Web of Science ®Google Scholar
• OPPENHEIM JJ, BIRAGYN A, KWAK LW, TANG D: Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann. Rheum. Dis. (2003) 62(Suppl. II):17-21.
   Web of Science ®Google Scholar
• HANCOCK RE, BROWN KL, MOOKHERJEE N: Host defence peptides from invertebrates – emerging antimicrobial strategies. Immunobiology (2006) 211(4):315-322.
   PubMed Web of Science ®Google Scholar
• MURRAY R: Staphylococcus aureus infective endocarditis: diagnosis and management guidelines. Int. Med. J. (2005) 35:S25-S44.
   Web of Science ®Google Scholar
• EL-AZIZI M, RAO S, KANCHANAPOOM T, KHARDORI N: In vitro activity of vancomyin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococcus. Ann. Clin. Microbiol. Antimicrob. (2005) 4:2.
   PubMedGoogle Scholar
• FALAGAS ME, MANTA KG, NTZIORA F, VARDAKAS KZ: Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J. Antimicrob. Chemother. (2006) 52(2):273-280.
   Google Scholar
• WEIGELT J, ITANI K, STEVENS D, LAU W, DRYDEN M, KNIRSCH C; LINEZOLID CSSTI STUDY GROUP: Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. (2005) 49(6):2260-2266.
   PubMed Web of Science ®Google Scholar
• WUNDERINK RG, CAMMARATA SK, OLIPHANT TH, KOLLEF MH: Continuation of a randomised, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. (2003) 36(3):159-168.
   Google Scholar
• DREW RH, PERFECT JR, SRINATH L, KURKIMILIS E, DOWZICKY M, TALBOT GH; for the SYNERCID EMERGENCY-USE STUDY GROUP: Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J. Antimicrob. Chemother. (2000) 46(5):775-780.
   PubMed Web of Science ®Google Scholar
• BISHOP E, MELVANI S, HOWDEN BP, CHARLES PGP, GRAYSON ML: Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob. Agents Chemother. (2006) 50(4):1599-1602.
   PubMed Web of Science ®Google Scholar
• POTOSKI BA, ADAMS J, CLARKE L, et al.: Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin. Infect. Dis. (2006) 43(2):165-171.
   PubMed Web of Science ®Google Scholar
• WERNER G, CUNY C, SCHMITZ F-J, WITTE W: Methicillin-resistant, quinupristin–dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides. J. Clin. Microbiol. (2001) 39(10):3586-3590.
   PubMed Web of Science ®Google Scholar
• LIPSKY BA, STOUTENBURGH U: Daptomycin for treating infected diabetic foot ulcers: evidence from a randomised, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J. Antimicrob. Chemother. (2005) 55(2):240-245.
   PubMed Web of Science ®Google Scholar
• FOWLER VG, BOUCHER HW, COREY R et al.: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. (2006) 355(7):653-665.
   PubMed Web of Science ®Google Scholar
• BREEDT J, TERAS J, GARDOVSKIS J et al.; TIGECYCLINE 305 STUDY GROUP: Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind Phase 3 comparison study with vancomycin–aztreonam. Antimicrob. Agents Chemother. (2005) 49(11):4658-4666.
   PubMed Web of Science ®Google Scholar
• BABINCHAK T, ELLIS-GROSSE E, DARTOIS N, ROSE GM, LOH E; TIGECYCLINE 301 STUDY GROUP; TIGECYCLINE 306 STUDY GROUP: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. (2005) 41(Suppl. 5):354-366.
   PubMed Web of Science ®Google Scholar
• PATEL JB, JEVITT LA, HAGEMAN J, MCDONALD LC, TENOVER FC: An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. (2006) 42(11):1652-1653.
   PubMed Web of Science ®Google Scholar
• MANGILI A, BICA I, SNYDMAN DR, HAMER DH: Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. (2005) 40(7):1058-1060.
   PubMed Web of Science ®Google Scholar
• HIRSCHWERK D, GINOCCHIO CC, BYTHROW M, CONDON S: Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect. Control Hosp. Epidemiol. (2006) 27(3):315-317.
   PubMed Web of Science ®Google Scholar
• PETTI CA, FOWLER VG Jr: Staphylococcus aureus bacteremia and endocarditis. Infect. Dis. Clin. North Am. (2002) 16(2):413-435.
   PubMed Web of Science ®Google Scholar
• GOLDMAN PL, PETERSDORF RG: Importance of beta-lactamase inactivation in treatment of experimental endocarditis caused by Staphylococcus aureus. J. Infect. Dis. (1980) 141(3):331-337.
   PubMed Web of Science ®Google Scholar
• CHANG FY, MACDONALD BB, PEACOCK JE Jr et al.: A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (2003) 82(5):322-332.
   PubMed Web of Science ®Google Scholar
• SMALL PM, CHAMBERS HF: Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. (1990) 34(6):1227-1231.
   PubMed Web of Science ®Google Scholar
• SORRELL TC, PACKHAM DR, SHANKER S, FOLDES M, MUNRO R: Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann. Intern. Med.(1982) 97(3):344-350.
   PubMed Web of Science ®Google Scholar
• GILBERT DN, WOOD CA, KIMBROUGH RC; The INFECTIOUS DISEASES CONSORTIUM OF OREGON: Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus vascular infection. Antimicrob. Agents Chemother. (1991) 35(1):79-87.
   PubMed Web of Science ®Google Scholar
• RUIZ ME, GUERRERO IC, TUAZON CU: Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin. Infect. Dis. (2002) 35(8):1018-1020.
   PubMed Web of Science ®Google Scholar
• SMITH AW: Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems? Adv. Drug Deliv. Rev. (2005) 57:1539-1550.
   PubMed Web of Science ®Google Scholar
• ZIMMERLI W, TRAMPUZ A, OSCHSNER PE: Prosthetic-joint infections. New Engl. J. Med. (2004) 351:1645-1654.
   PubMed Web of Science ®Google Scholar
• CHAMIS A, PETERSON G, CABELL C: Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation (2001) 104:1029-1033.
   PubMed Web of Science ®Google Scholar
• SEGRETI J, NELSON JA, TRENHOLME GM: Prolonged suppressive antibiotic therapy for infected orthopaedic prostheses. Clin. Infect. Dis. (1998) 27(4):711-713.
   PubMed Web of Science ®Google Scholar
• DAROUICHE RO, MANSOURI MD: Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vitro. J. Infect. (2005) 50(3):206-209.
   PubMed Web of Science ®Google Scholar
• JOHNSON PD, MARTIN R, BURRELL LJ et al.: Efficacy of an alcohol/chlorhexidine hand hygiene program in a hospital with high rates of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection. Med. J. Aust. (2005) 183(10):509-514.
   Google Scholar
• HARBATH S, MARTIN Y, ROHNER P, HENRY N, AUCKENTHALER R, PITTET D: Effect of delayed infection control measures on a hospital outbreak of methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. (2000) 46(1):43-49.
   PubMed Web of Science ®Google Scholar
• PITTET D: Hand hygiene:improved standards and practice for hospital care. Curr. Opin. Infect. Dis. (2003) 16(4):327-335.
   PubMed Web of Science ®Google Scholar
• WALKER ES, VASQUEZ JE, DULA R, BULLOCK H, SARUBBI FA: Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect. Control Hosp. Epidemiol. (2003) 24(5):342-346.
   PubMed Web of Science ®Google Scholar
• HADA T, FURUSE S, MATSUMOTO Y et al.: Comparison of the effects in vitro of tea tree oil and plaunotol on methicillin-susceptible and methicillin-resistant strains of Staphylococcus aureus. Microbios. (2001) 106(Suppl. 2):133-141.
   PubMedGoogle Scholar
• DRYDEN MS, DAILLY S, CROUCH M: A randomised, controlled trail of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J. Hosp. Infect. (2004) 56(4):283-286.
   PubMed Web of Science ®Google Scholar
• CAELLI M, PORTEOUS J, CARSON CF, HELLER R, RILEY TV: Tea tree oil as an alternative topical decolonisation agent for methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. (2000) 46(3):236-237.
   PubMed Web of Science ®Google Scholar
• DIEKEMA DJ, JONES RN: Oxazolidinone antibiotics. Lancet (2001) 358(9297):1975-1981.
   PubMed Web of Science ®Google Scholar
• GUAY DR: Daptomycin: the first approved lipopeptide antimicrobial. Consult. Pharm. (2004) 19(7):614-628.
   PubMedGoogle Scholar
• BETRIU C, CULEBRAS E, RODRIGEZ-AVIAL I, GOMEZ M, SACHEZ A, PICAZO JJ: In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance. Antimicrob. Agents Chemother. (2004) 48(1):323-325.
   PubMed Web of Science ®Google Scholar
• LEE MC, RIOS AM, ATEN MF et al.: Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr. Infect. Dis. J. (2004) 23(2):123-127.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-AGUILAR G, HAMMERMAN WA, MASON EO, KAPLAN SL: Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in children. Pediatr. Infect. Dis. J. (2003) 22(7):593-598.
   PubMed Web of Science ®Google Scholar
• FRANK AL, MARCINAK JF, MANGAT PD et al.: Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr. Infect. Dis. J. (2002) 21(6):530-534.
   PubMed Web of Science ®Google Scholar
• AL-SHAWWA BA, WEGNER D: Trimethoprim-sulfamethoxazole plus topical antibiotics as therapy for acute otitis media with otorrhea caused by community-acquired methicillin-resistant Staphylococcus aureus in children. Arch. Otolaryngol. Head Neck Surg. (2005) 131(9):782-784.
   PubMed Web of Science ®Google Scholar
• LEDER K, TURNIDGE JD, KORMAN TM, GRAYSON ML: The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. J. Antimicrob. Chemother. (1999) 43(1):113-118.
   PubMed Web of Science ®Google Scholar
• MCNEIL JJ, GRABSCH EA, MCDONALD MM: Postmarketing surveillance: strengths and limitations. The flucloxacillin-dicloxacillin story. Med. J. Aust. (1999) 170(6):270-273.
   PubMed Web of Science ®Google Scholar
• RAYNER C, MUNCKHOF WJ: Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus. Int. Med. J. (2005) 35:S3-S16.
   Web of Science ®Google Scholar
• GRAYSON ML, MCDONALD M, GIBSON K et al.: Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Clin. Infect. Dis.. (2002) 34(11):1440-1448.
   PubMed Web of Science ®Google Scholar
• MORGAN GJ, KRISHNADASAN A, GORWITZ RJ et al.: Methicillin-resistant S. aureus infections among patients in the emergency department. New Eng. J. Med. (2006) 355:666-674.
   PubMed Web of Science ®Google Scholar
• DRINKOVIC D, FULLER ER, SHORE KP, HOLLAND DJ, ELLIS-PEGLER R: Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J. Antimicrob. Agents Chemother. (2001) 48(2):315-329.
   Google Scholar
• SCHMITZ FJ, FLUIT AC, HAFNER D et al.: Development of resistance to ciprofloxacin, rifampicin and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates. Antimicrob. Agents Chemother. (2000) 44(11):3229-3231.
   PubMed Web of Science ®Google Scholar
• JU O, WOOLLEY M, GORDON D: Emergence and spread of rifampicin resistant, methicillin-resistant Staphylococcus aureus during vancomycin–rifampicin combination therapy in an intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis. (2006) 25(1):61-62.
   PubMed Web of Science ®Google Scholar
• TURNIDGE J, COLLINGNON P: Resistance to fusidic acid. Int. J. Antimicrob. Agents (1999) 12(Suppl. 2):S35-S44.
   Web of Science ®Google Scholar
• HOWDEN BP, GRAYSON ML: Dumb and dumber – the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin. Infect. Dis. (2006) 42(3):394-400.
   PubMed Web of Science ®Google Scholar
• MASON BW: Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and the use of topical fusidic acid: a retrospective case-control study. Int. J. Antimicrob. Agents (2004) 23(3):300.
   PubMed Web of Science ®Google Scholar
• SHOPSIN B, ZHAO X, KREISWIRTH BN et al.: Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus? Int J. Antimicrob. Agents (2004) 24(1):32-34.
   PubMed Web of Science ®Google Scholar
• WEBER SG, GOLD HS, HOOPER DC, KARCHMER AW, CARMELI Y: Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg. Infect. Dis. (2003) 9(11):1415-1422.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ N, QUINN EL, SARAVOLATZ LD: Trimethoprim–sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann. Intern. Med. (1992) 117(5):390-398.
   PubMed Web of Science ®Google Scholar
• SANDRI AM, DALAROSA MG, RUSCHEL DE ALCANTARA L, DA SILVA ELIAS L, ZAVASCKI AP: Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect. Control Hosp. Epidemiol. (2006) 27(2):185-187.
   PubMed Web of Science ®Google Scholar
• DUPEYRON C, CAMPILLO B, RICHARDET JP, SOUSSY CJ: Long-term efficacy of mupirocin in the prevention of infections with methicillin-resistant Staphylococcus aureus in a gastroenterology unit. J. Hosp. Infect. (2006) 63(4):385-392.
   PubMed Web of Science ®Google Scholar
• PEREZ-ROTH E, LOPEZ-AGUILAR C, ALCOBA-FLOREZ J, MENDEZ-ALVAREZ S: High-level mupirocin resistance within methicillin-resistant Staphylococcus aureus pandemic lineages. Antimicrob. Agents Chemother. (2006) 50(9):3207-3211.
   PubMed Web of Science ®Google Scholar
• MCKINNON PS, LODISE TP Jr, RYBAK MJ: Impact of initial treatment with vancomycin versus a beta-lactam on outcomes and costs of methicillin-susceptible Staphylococcus aureus bacteremia (MSSAB) [abstract 579]. In: Program and abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America. Chicago, Illinois, USA, 24 – 27 October (2002).
   Google Scholar
• LIU C, CHAMBERS HF: Staphylococcus aureus with heterogenous resistance to vancomycin: epidemiology, clinical significance and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. (2003) 47(10):3040-3045.
   PubMed Web of Science ®Google Scholar
• HOWDEN BP, JOHNSON PD, WARD PB, STINEAR TP, DAVIES JK: Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. (2006) 50(9):3039-3047.
   PubMed Web of Science ®Google Scholar
• STREIT JM, SADER HS, FRITSCHE TR, JONES RN: Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn. Microbiol. Infect. Dis. (2005) 53(4):307-310.
   PubMed Web of Science ®Google Scholar
• LIPSKY BA, ITANI K, NORDEN C; THE LINEZOLID DIABETIC FOOT INFECTIONS STUDY GROUP: Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/ amoxicillin-clavulanate. Clin. Infect. Dis. (2004) 38(1):17-24.
   PubMed Web of Science ®Google Scholar
• SILVERMAN JA, MORTIN LI, VANPRAAGH AD, LI T, ALDER J: Inhibition of daptomycin by pulmonary surfactant: in vitro modelling and clinical impact. J. Infect. Dis. (2005) 191(12):2149-2152.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-IOANAS M, DE ROUX A, LODE H: New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient. Curr. Opin. Crit. Care (2005) 11(5):481-486.
   PubMed Web of Science ®Google Scholar
• JAKSIC B, MARTINELLI G, PEREZ-OTEYZA J, HARTMAN CS, LEONARD LB, TACK KJ: Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin. Infect. Dis. (2006) 42(5):597-607.
   PubMed Web of Science ®Google Scholar
• TAYLOR JJ, WILSON JW, ESTES LL: Linezolid and serotonergic drug interactions: a retrospective survey. Clin. Infect. Dis. (2006) 43(2):180-187.
   PubMed Web of Science ®Google Scholar
• JONES RN, BALLOW CH, BIEDENBACH DJ, DEINHART JA, SCHENTAG JJ: Antimicrobial activity of quinupristin-dalfopristin (RP-59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn. Microbiol. Infect. Dis. (1998) 31(3):437-451.
   PubMed Web of Science ®Google Scholar
• NICHOLS RL, GRAHAM DR, BARRIERE SL et al.: Treatment of hospitalised patients with complicated gram positive skin and skin structure infections: two randomised, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J. Antimicrob. Chemother. (1999) 44(2):263-273.
   PubMed Web of Science ®Google Scholar
• RAAD I, BOMPART F, HACHEM R: Prospective, randomised dose-ranging open Phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. (1999) 18(3):199-202.
   PubMed Web of Science ®Google Scholar
• FAGON J, PATRICK H, HAAS DW et al.: Treatment of gram-positive nosocomial pneumonia. Prospective randomised comparison of quinupristin/dalfopristin versus vancomyin. Nosocomial Pneumonia Group. Am. J. Respir. Crit. Care Med. (2000) 161(3):753-762.
   PubMed Web of Science ®Google Scholar
• JOHNSON AP, MUSHTAQ S, WARNER M, LIVERMORE DM: Activity of daptomycin against multi-resistant Gram positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int. J. Antimicrob. Agents. (2004) 24(4):315-319.
   PubMed Web of Science ®Google Scholar
• PANKEY G, ASHCRAFT D, PATEL N: In vitro synergy of daptomycin plus rifampicin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob. Agents Chemother. (2005) 49(12):5166-5168.
   PubMed Web of Science ®Google Scholar
• SEGRETI JA, CRANK CW, FINNEY MS: Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy (2006) 26(3):347-352.
   PubMed Web of Science ®Google Scholar
• GRAYSON ML: The treatment triangle for staphylococcal infections. N. Engl. J. Med. (2006) 355(7):724-727.
   PubMed Web of Science ®Google Scholar
• RAO N, REGALLA DM: Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. Clin. Orthop. Rel. Res. (2006) 451:34-37.
   PubMed Web of Science ®Google Scholar
• ECHEVARRIA K, DATTA P, CADENA J, LEWIS JS II: Severe myopathy and possible hepatotoxity related to daptomycin. J. Antimicrob. Chemother. (2005) 55(4):599-600.
   PubMed Web of Science ®Google Scholar
• PAPADOPOULOS S, BALL AM, LIEWER SE, MARTIN CA, WINSTEAD PS, MURPHY BS: Rhabdomyolysis during therapy with daptomycin. Clin. Infect. Dis. (2006) 42(12):e108-e110.
   PubMed Web of Science ®Google Scholar
• PETERSEN PJ, JACOBUS NV, WEISS WJ, SUM PE, TESTA RT: In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butyl-glycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. (1999) 43:738-744.
   PubMed Web of Science ®Google Scholar
• GARCIA-LARA J, MASALHA M, FOSTER SJ: Staphylococcus aureus: the search for novel targets. Drug Discov. Today (2005) 10(9):643-651.
   PubMed Web of Science ®Google Scholar
• ABBANAT D, MACIELAG M, BUSH K: Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert. Opin. Investig. Drugs. (2003) 12(3):379-399.
   PubMed Web of Science ®Google Scholar
• RAZ R, MIRON D, COLODNER R, STALER Z, SAMORA Z, KENESS Y: A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch. Intern. Med. (1996) 156(10):1109-1112.
   PubMed Web of Science ®Google Scholar
• DRUSANO GL, LOUIE A, DEZIEL M, GUMBO T: The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clin. Infect. Dis. (2006) 42(4):525-532.
   PubMed Web of Science ®Google Scholar
• FOSTER TJ: Immune evasion by staphylococci. Nat. Rev. Microbiol. (2005) 3(12):948-958.
   PubMed Web of Science ®Google Scholar
• SAIDO-SAKANAKA H, ISHIBASHI J, SAGISAKA A, MOMOTANI E, YAMAKAWA M: Synthesis and characterization of bacterial oligopeptides designed on the basis of an insect antibacterial peptide. Biochem. J. (1999) 338(1):29-33.
   PubMed Web of Science ®Google Scholar
• FABER C, STALLMANN HP, LYARUU DM et al.: Release of antimicrobial peptide Dhvar-5 from polymethylmethacrylate beads. J. Antimicrob. Chemother. (2003) 51(6):1359-1364.
   PubMed Web of Science ®Google Scholar
• ZASLOFF M. Antimicrobial peptides of multicellular organisms. Nature (2002) 415(6870):389-395.
   PubMed Web of Science ®Google Scholar
• MATSUZAKI S, RASHEL M, UCHIYAMA J et al.: Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J. Infect. Chemother. (2005) 11(5):211-219.
   PubMed Web of Science ®Google Scholar
• WILLS QF, KERRIGAN C, SOOTHILL JS: Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob. Agents Chemother. (2005) 49:1220-1221.
   PubMed Web of Science ®Google Scholar
• MATSUZAKI S, YASUDA M, NISHIKAWA H et al.: Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage Mr11. J. Infect. Dis. (2003) 187(4):613-624.
   PubMed Web of Science ®Google Scholar
• O’FLAHERTY S, ROSS RP, MEANY W, FITZGERALD GF, ELBREKI MF, COFFEY A: Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl. Environ. Microbiol. (2005) 71(4):1836-1842.
   PubMed Web of Science ®Google Scholar
• YACOBY I, SHAMIS M, BAR H, SHABAT D, BENHAR I: Targeting antibacterial agents by using drug-carrying filamentous bacteriophages. Antimicrob. Agents Chemother. (2006) 50(6):2087-2097.
   PubMed Web of Science ®Google Scholar
• PROJAN S: Phage-inspired antibiotics? Nat. Biotechnol. (2004) 22(2):167-168.
   PubMed Web of Science ®Google Scholar
• WU JA, KUSUMA C, MOND JJ, KOKAI-KUN-JF: Lysostaphin disrupts Staphylococcus aureus and staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob. Agents Chemother. (2003) 47(11):3407-3414.
   PubMed Web of Science ®Google Scholar
• DONLAN RM, COSTERTON JW: Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Micro. Rev. (2002) 15:167-193.
   PubMed Web of Science ®Google Scholar
• YARWOOD JM, SCHLIEVERT PM: Quorum sensing in staphylococcal infections. J. Clinical Invest. (2003) 112(11):1620-1625.
   PubMed Web of Science ®Google Scholar
• BALABAN N, GOV Y, BITLER A, BOELAERT JR: Prevention of Staphylococcus aureus biofilm on dialysis catheters and adherence to human cells. Kidney Int. (2003) 63(1):340-345.
   PubMed Web of Science ®Google Scholar
• DITIZIO V, FERGUSON GW, MITTELMAN MW, KHOURY AE, BRUCE AW, DICOSMO F: A liposomal hydrogel for the prevention of bacterial adhesion to catheters. Biomaterials (1998) 19(20):1877-1884.
   PubMed Web of Science ®Google Scholar
• PROJAN SJ, NESIN M, DUNMAN PM: Staphylococcal vaccines and immunotherapy: to dream the impossible dream? Curr. Opin. Pharmacol. (2006) 6(5):1-7.
   Web of Science ®Google Scholar
• FREER JH, ARBUTHNOTT JP: Toxins of Staphylococcus aureus. Pharmacol. Ther. (1982) 19(1):55-106.
   PubMed Web of Science ®Google Scholar
• JARRAUD S, MOUGEL C, THIOLOUSE J et al.: Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles) and human disease. Infec. Immun. (2002) 70(2):631-641.
   PubMed Web of Science ®Google Scholar
• LLEWELYN M, COHEN J: Superantigen antagonist peptides. Critical Care (2001) 5:53-55.
   PubMed Web of Science ®Google Scholar
• HUNTZINGER E, BOISSET S, SAVEANU C et al.: Staphylococcus aureus RNAIII and the endoribonuclease III coordinately regulate spa gene expression. EMBO J. (2005) 24(4):824-835.
   PubMed Web of Science ®Google Scholar
• BALABAN N, GOLDKORN T, NHAN RT et al.: Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. Science (1998) 280(5362):438-440.
   PubMed Web of Science ®Google Scholar
• MALABARBA A, GOLDSTEIN BP: Origin, structure and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother. (2005) 55 (Supp. 2):S15-S20.
   Web of Science ®Google Scholar
• RAAD I, DAROUICHE R, VAZQUEZ J, et al.: Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin. Infect. Dis. (2005) 40(3):374-380.
   PubMed Web of Science ®Google Scholar
• SELTZER E, DORR MB, GOLDSTEIN BP, PERRY M, DOWELL JA, HENKEL T; DALBAVACIN SKIN AND SOFT-TISSUE INFECTION STUDY GROUP: Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft tissue infections. Clin. Infect. Dis. (2003) 37(10):1298-1303.
   PubMed Web of Science ®Google Scholar
• JAUREGUI LE, BABAZADEH S, SELTZER E. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. (2005) 41(10):1407-1415.
   PubMed Web of Science ®Google Scholar
• STRYJEWSKI ME, O’RIORDAN WD, LAU WK et al.; for the FAST INVESTIGATOR GROUP: Televancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin. Infect. Dis. (2005) 40(11):1601-1607.
   PubMed Web of Science ®Google Scholar
• GIAMARELLOU H, O’RIORDAN W, HARRIS H, OWEN S, PORTER S, LOUTIT J: Phase 3 trial comparing 3 – 7 days of oritavancin vs. 10 – 14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSSI) [abstract L-739a]. In: Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington DC, USA (2003).
   Google Scholar
• SMITH K, TANAKA SK, APPELBAUM PC: MK-2764/PTK-0796, a new aminomethylcycline, is potent against all S. aureus strains tested, irrespective of antibiotic resistance. In: Program and Abstracts, 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (2006). Poster F1-1971.
   Google Scholar
• BOGDANOVICH T, ESEL D, KELLY LM et al.: Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents. Antimicrob. Agents Chemother. (2005) 49(8):3325-3333.
   PubMed Web of Science ®Google Scholar
• HARA S, ASAOKA A, YAMAKAWA M: Effect of moricin, a novel anti-bacterial peptide of Bonbyx mori (Lepidoptera:Bombycidae) on the growth of methicillin-resistant Staphylococcus aureus (MRSA). Appl. Entomol. Zool. (1996) 31:465-466.
   Web of Science ®Google Scholar
• YAMADA K, NATORI S: Purification, sequence and anti-bacterial activity of two novel sapecin homologues from Sarcophaga embryonic cells: similarity of sapecin B to charybdotoxin. Biochemistry (1993) 291(1):275-279.
   Google Scholar
• PROJAN S: Why is big Pharma getting our of antibacterial drug discovery? Curr. Opin. Microbiol. (2003) 6(5):427-430.
   PubMed Web of Science ®Google Scholar
• TALLY FP, DEBRUIN MF: Development of daptomycin for Gram-positive infections. J. Antimicrob. Chemother. (2000) 46(4):523-526.
   PubMed Web of Science ®Google Scholar
• MITCHELL DH, HOWDEN BP: Diagnosis and management of Staphylococcus aureus bacteraemia. Intern. Med. J. (2005) 35(Suppl. 2):S17-S24.
   PubMedGoogle Scholar
• GOSBELL IB: Diagnosis and management of catheter-related bloodstream infections due to Staphylococcus aureus. Intern. Med. J. (2005) 35(Suppl. 2):S45-S62.
   PubMed Web of Science ®Google Scholar
• DAVIS JS: Management of bone and joint infections due to Staphylococcus aureus. Intern. Med. J. (2005) 35(Suppl. 2):S79-S96.
   PubMed Web of Science ®Google Scholar
• ROBERTS S, CHAMBERS S: Diagnosis and management of Staphylococcus aureus infections of the skin and soft tissue. Intern. Med. J. (2005) 35(Suppl. 2):S97-S105.
   PubMed Web of Science ®Google Scholar
• GOSWITZ JJ, WILLARD KE, FASCHING CE, PETERSON LR: Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing. Antimicrob. Agents Chemother. (1992) 36(5):1166-1169
   PubMed Web of Science ®Google Scholar
• YOO JI, SHIN ES, OK CHA J et al.: Clonal dissemination and mupA gene polymorphism of mupirocin-resistant Staphylococcus aureus isolates from long-term-care facilities in South Korea. Antimicrob. Agents Chemother. (2006) 50(1):365-367.
   PubMed Web of Science ®Google Scholar